Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$146.73 USD

146.73
848,529

+2.60 (1.80%)

Updated Aug 8, 2024 04:00 PM ET

After-Market: $146.75 +0.02 (0.01%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Sweta Killa headshot

Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4

by Sweta Killa

Investors could be well served by ETFs and stocks from sectors that house top-ranked industries.

Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CTLT or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Kinjel Shah headshot

Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HKMPF vs. NBIX: Which Stock Is the Better Value Option?

Lannett (LCI) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Neurocrine Biosciences (NBIX) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Neurocrine Biosciences (NBIX).

Why Neurocrine (NBIX) Could Be Positioned for a Surge

by Zacks Equity Research

Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Moving Average Crossover Alert: Neurocrine Biosciences

by Zacks Equity Research

Neurocrine Biosciences, Inc. (NBIX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises

by Zacks Equity Research

Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil

by Zacks Equity Research

Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.

Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed second-quarter results.

Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.

Why Neurocrine (NBIX) Might be Well Poised for a Surge

by Zacks Equity Research

Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Neurocrine (NBIX) Ahead of Earnings?

by Zacks Equity Research

Neurocrine (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

by Zacks Equity Research

The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

CTLT or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 35.71% and -0.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.